Funding sources G.Y. is funded by NIH Ro-11R01AR055902-01A1.
Targeted treatment of pruritus: a look into the future
Version of Record online: 30 MAY 2011
© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011
British Journal of Dermatology
Volume 165, Issue 1, pages 5–17, July 2011
How to Cite
Tey, H.L. and Yosipovitch, G. (2011), Targeted treatment of pruritus: a look into the future. British Journal of Dermatology, 165: 5–17. doi: 10.1111/j.1365-2133.2011.10217.x
Conflicts of interest G.Y. is on the advisory board of GlaxoSmithKline and served as consultant for Regeneron, Johnson & Johnson and Unilever. H.L.T. has no conflicts of interest.
- Issue online: 24 JUN 2011
- Version of Record online: 30 MAY 2011
- Accepted manuscript online: 11 JAN 2011 12:40AM EST
- Accepted for publication 2 January 2011
Recent advances in pruritus research have elucidated mediators and neuronal pathways involved in itch transmission, and this fast emerging knowledge may possibly be translated into new therapies in the near future. In the skin and peripheral nerves, potential mediator and receptor therapeutic targets include the H4 histamine receptor, protease-activated receptor 2, serine proteases, cathepsin S, peripheral mu- and kappa-opioid receptors, interleukin-31, transient receptor potential vanilloid 1 and 3, fatty acid amide hydrolase, nerve growth factor and its receptor, acetylcholine, and the Mas-related G protein-coupled receptors. In the spinal cord, gastrin-related peptide and its receptor, as well as substance P and its receptor neurokinin receptor-1 serve as potential therapeutic targets. In the brain, reduction of itch perception and modulation of emotions may possibly be achieved through drugs acting on the anterior cingulate cortex. Clinically, management of pruritus should be instituted early and should address the skin pathology, peripheral neuropathy, central sensitization, and the cognito-affective aspects of the disease.